newsfilter
← Latest News
Business Wire·

New Case Study: bioAffinity Technologies' CyPath® Lung Diagnostic Supports Physician's Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy

BIAFBIAFW
  • A 70-year-old high-risk female patient presented with a 30-mm pulmonary nodule where standard imaging & risk models indicated a high likelihood of cancer.
  • The CyPath® Lung noninvasive sputum test returned a negative result ("Unlikely Malignancy"), suggesting the nodule was inflammation rather than cancer.
  • A follow-up CT scan confirmed the 30-mm nodule had completely resolved, validating the test's assessment & avoiding an unnecessary biopsy.
  • In a clinical trial of high-risk patients with small indeterminate nodules, CyPath® Lung demonstrated 92% sensitivity, 87% specificity, & 88% accuracy for detecting lung cancer.
  • bioAffinity Technologies markets CyPath® Lung as a noninvasive diagnostic tool that uses flow cytometry & artificial intelligence to identify malignancy in sputum samples.
  • The test is currently offered as a CLIA-regulated Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies.
  • The case study illustrates how the test can help physicians defer risky invasive procedures for patients with complicating health conditions like emphysema.